AJP - Lung Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Lung Cell Mol Physiol 293: L1-L8, 2007. First published March 23, 2007; doi:10.1152/ajplung.00378.2006
1040-0605/07 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
293/1/L1    most recent
00378.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arciniegas, E.
Right arrow Articles by Stenmark, K. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arciniegas, E.
Right arrow Articles by Stenmark, K. R.

INVITED REVIEW

Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension

Enrique Arciniegas,1 Maria G. Frid,2 Ivor S. Douglas,3 and Kurt R. Stenmark2

1Laboratorio de Microscopia Electrónica, Servicio Autónomo Instituto de Biomedicina, Facultad de Medicina, Universidad Central de Venezuela, Caracas, Venezuela; 2Pediatric Critical Care Medicine, Developmental Lung Biology Laboratory and Cardiovascular Pulmonary Research, University of Colorado Health Sciences Center, Denver; and 3Pulmonary Sciences and Critical Care Medicine, Denver Health and University of Colorado Health Sciences Center, Denver, Colorado


    ABSTRACT
 TOP
 ABSTRACT
 GRANTS
 REFERENCES
 
All forms of pulmonary hypertension are characterized by structural changes in pulmonary arteries. Increased numbers of cells expressing {alpha}-smooth muscle ({alpha}-SM) actin is a nearly universal finding in the remodeled artery. Traditionally, it was assumed that resident smooth muscle cells were the exclusive source of these newly appearing {alpha}-SM actin-expressing cells. However, rapidly emerging experimental evidence suggests other, alternative cellular sources of these cells. One possibility is that endothelial cells can transition into mesenchymal cells expressing {alpha}-SM actin and that this process contributes to the accumulation of SM-like cells in vascular pathologies. We review the evidence that endothelial-mesenchymal transition is an important contributor to cardiac and vascular development as well as to pathophysiological vascular remodeling. Recent work has provided evidence for the role of transforming growth factor-beta, Wnt, and Notch signaling in this process. The potential roles of matrix metalloproteinases and serine proteases are also discussed. Importantly, endothelial-mesenchymal transition may be reversible. Thus insights into the mechanisms controlling endothelial-mesenchymal transition are relevant to vascular remodeling and are important as we consider new therapies aimed at reversing pulmonary vascular remodeling.

transforming growth factor-beta; pulmonary vascular development; E-cadherin


ALL FORMS OF CHRONIC PULMONARY HYPERTENSION are characterized by cellular and structural changes in the walls of pulmonary arteries. Virtually all of these changes are characterized, to a greater or lesser degree, by increased numbers of cells expressing {alpha}-smooth muscle ({alpha}-SM) actin (44, 76, 109). Albeit, neither the origin(s) of these cells nor the molecular mechanisms operating to cause their accumulation have been fully elucidated.

Traditionally, it has been thought that the SM-like cells that express {alpha}-SM actin and accumulate in vascular lesions were derived from the proliferative expansion of resident vascular smooth muscle cells (SMC) or adventitial fibroblasts through the processes of dedifferentiation of the former or differentiation of the latter. Over the years, however, this concept has been challenged by new experimental data suggesting many other possible sources of {alpha}-SM actin-expressing cells (SM-like cells and/or myofibroblasts) in various vascular diseases including pulmonary hypertension. Circulating progenitor cells have been shown to be recruited to sites of vascular injury and to assume SM-like phenotype (29, 57, 87). Resident vascular progenitor cells have also been demonstrated to express SM-like characteristics in several vascular injury states (41, 95). Finally, the possibility that endothelial cells have the capability of transitioning into a mesenchymal or SM-like phenotype has been raised. It is toward this last possibility (i.e., endothelial-mesenchymal transition) that this review is directed.

Many terms have been used to describe the process through which endothelial cells lose endothelial characteristics and gain expression of mesenchymal, myofibroblast-like characteristics. In this review, we will use the term endothelial-mesenchymal transition (EnMT). We will name it transition, rather than transformation or transdifferentiation, to keep this review in line with the current thinking of epithelial biologists, where the process of epithelial-mesenchymal transition (EMT) has been more thoroughly investigated (38, 48, 74, 81, 88, 97). The term transition seems more appropriate than transformation or transdifferentiation, because transformation classically describes oncogenic conversion, and transdifferentiation refers to a phenotypic switch of cells from one differentiated phenotype into another differentiated phenotype. Our intention is to first, briefly review EMT, the transition of epithelial cells toward a mesenchymal phenotype, since this process can lay the groundwork for understanding EnMT. We will then review the evidence for EnMT in vascular endothelial cells and address its potential mechanisms. The mechanisms identified so far in EnMT will be compared with those of EMT, noting that there are a great many similarities (Table 1).


View this table:
[in this window]
[in a new window]

 
Table 1. Comparison of EMT to EnMT: physiology, pathophysiology, and mechanisms

 
EMT. EMT is a process in which epithelial cells lose their cell-to-cell contacts and polarity and undergo a dramatic remodeling of the cytoskeleton (37, 48, 52, 74, 81, 88, 97). During this process, which can be initiated by factors including transforming growth factor (TGF)-beta, fibroblast growth factor (FGF)-2, epithelial growth factor (EGF), hepatocyte growth factor (HGF)/scatter factor (SF), and H-Ras, there is a marked repression of epithelial markers [E-cadherin, {alpha}-, beta-, and {gamma}-catenins, desmoplakin, zona occludens-1 (ZO-1), and cytokeratin-18]. Concurrent with this loss of epithelial cell antigens, cells begin to express mesenchymal antigens, including FSP-1, {alpha}-SM actin, fibronectin, and type I and III collagens, and to manifest a proliferative and migratory phenotype. The transition of epithelial cells toward a mesenchymal phenotype occurs at many critical steps during embryonic development. The developmental formation of various organs in vertebrates, such as the neural crest, heart, musculoskeletal system, cranial facial structures, and peripheral nervous system, relies on EMT (37, 48, 52, 74, 81, 88, 97). It should be noted that during development, mesenchymal cells can also participate in the formation of epithelial organs through a mesenchymal-epithelial transition (MET) (38, 97). This concept has potential relevance to treatment of diseases where EMT may be playing a role and is discussed below (74, 81).

In addition to its known role in development, recent data suggest EMT is important in cancer biology, especially as it relates to the metastatic capabilities of epithelial tumors. EMT is an important event in the progression of many carcinomas (37, 74, 81, 97), where epithelial cells transition toward a mesenchymal phenotype, leave the organized epithelial layer, and acquire an invasive phenotype, thus initiating metastasis. This transition has been shown to confer resistance to apoptosis in murine epithelial cell lines (82). It has even been speculated that EMT is a permanent feature in mixed carcinoma/sarcoma tumors (74).

A role for EMT is also becoming increasingly clear during tissue injury leading to organ fibrosis (defined by deposition of collagens, elastin, tenascin, and other matrix proteins). For instance, EMT is associated with progressive fibrosis in kidney disease (48, 68, 69, 90, 112). In the normal kidney, fibroblasts are not particularly abundant. However, at the onset of fibrogenesis, there is a marked increase in the number of fibroblasts. It has recently been demonstrated in a model of renal fibrosis that at least one-third of the newly appearing fibroblasts are derived through a local EMT process (48, 112). Thus, it has been suggested that kidney fibrogenesis, to a great degree, is a local epithelial event (69). There is emerging evidence to suggest that EMT also contributes to the fibrotic responses observed in several lung pathologies, such as rejecting lung allografts, silica-induced lung carcinogenesis, and in idiopathic pulmonary fibrosis (14, 17, 103105).

EnMT. Less is known regarding EnMT than EMT. However, there is increasing experimental evidence to suggest that EnMT plays an important role during cardiovascular development and in various vascular pathologies. In the developing vertebrate embryo, the heart is the first organ to be formed, and its endocardial cells, initially expressing an endothelial phenotype (VE-cadherin, Tie-1/2, VEGFR 1/2, and PECAM/CD31) in the atrio-ventricular canal, give rise to the mesenchymal heart cushion cells through a process of EnMT and form the mesenchymal portion of cardiac septa and valves (10, 27, 54).

In addition to its role in heart development, several groups have provided evidence that EnMT is critical in early vascular development. Using ultrastructural, immunohistochemical, and cell culture approaches, Arciniegas et al. (4, 8) have shown that EnMT is an important event in aortic and pulmonary artery development. Using immunogold labeling techniques, DeRuiter et al. (24) showed that endothelial cells labeled at an early stage of development later (at the onset of SMC differentiation) appeared in the subendothelial space of the developing aorta and expressed {alpha}-SM actin. Development of the normal arterial intima, a process that begins relatively early in life, also appears to involve EnMT (4, 7). Morphological studies in human embryos suggest that endothelial-like cells may give rise to SMC during the maturation of both pulmonary arteries and veins (35, 36). Findings in experimental wound repair have suggested that EnMT may also take place in the adult, reporting that capillary endothelial cells could undergo conversion into interstitial connective tissue mesenchymal-like cells in granulation tissue (85). Others have observed that microvascular endothelial cells transitioned into mesenchymal cells in response to chronic inflammatory stimuli (56, 83). A possible role for EnMT in the neointimal thickening observed in transplant atherosclerosis and restenosis has also been suggested (11, 12, 62). In addition, it has recently been demonstrated that transdifferentiation of pulmonary arteriolar endothelial cells into SM-like cells occurs in hypoxia-induced pulmonary vascular remodeling and is regulated by myocardin (113).

A number of in vitro studies have demonstrated that endothelial cells from a variety of vascular beds retain the capability of transitioning into mesenchymal or even SM-like cells under a variety of culture conditions (4, 6, 30, 46). Endothelial cells derived from the adult bovine aorta convert to spindle-shaped {alpha}-SM actin-expressing cells when treated with TGF-beta1 (9). Certain murine endothelial-like cell lines irreversibly transform into mesenchymal cells upon overgrowth in culture (51).

One concern raised regarding the early reports describing EnMT was the possibility that the primary endothelial cell cultures were simply contaminated with small numbers of mesenchymal cells. The studies by Frid et al. (30) addressed this problem in more detail by using both fluorescent-activated cell sorting (FACS) and magnetic bead (Dynabeads) techniques to "purify" primary endothelial cell cultures based on elevated uptake of DiI-Ac-LDL or on PECAM-1/CD31 expression by endothelial cells to obtain endothelial cultures free of contamination with mesenchymal cells. These purified endothelial cell cultures, however, were still shown to give rise to colonies of mesenchymal and even SM-like cells when selection of endothelial cells was performed immediately (on day 1) after initiating primary cultures. In contrast, when endothelial cell selection was performed 5 or more days after establishing primary cultures, no mesenchymal cells were observed to appear. The possibility was raised that the endothelial-mesenchymal phenotypic switch had already occurred in these cultures before day 5, and the resulting endothelial-derived mesenchymal cells have therefore been eliminated by FACS or Dynabead sorting. Interestingly, these techniques are commonly used by investigators to eliminate mesenchymal contaminants in endothelial cultures derived from large arteries, and they are usually applied after expansion of cells in culture. In contrast, in studies of microvascular endothelial cells, sorting techniques are usually applied at the time of cell isolation, and the need for subsequent selective sorting has been noted as an essential requirement (39, 93, 101). Dermal microvascular endothelial cells, for example, are described as very susceptible to transitioning into mesenchymal cells (83). Thus these studies supported the idea that mesenchymal cells often observed in primary endothelial cultures can arise through the process of EnMT.

EnMT and EMT require loss of cell-cell contacts. Recent studies have provided evidence that loss of endothelial cell-cell contacts is a necessary step in progression of EnMT. We have reported that loss of cell-cell contacts (including loss of VE-cadherin expression) consistently preceded changes in endothelial cell morphology and the subsequent expression of {alpha}-SM actin (30). Alterations in cell morphology and upregulation of {alpha}-SM actin have also been observed in sparsely plated endothelial cell cultures maintained in the presence of TGF-beta1 (9). During chick embryo development, loss of cell-cell contacts, cell migration, and upregulation of {alpha}-SM actin expression (involving TGF-beta2 and -3 and BMP-2) have also been reported in the conversion of a subset of endocardial endothelial cells into mesenchymal cells (15, 54, 63). Based on these observations and other reports, it was proposed that the TGF-beta signal transduction pathway is critically involved in the loss of cell-cell contacts and therefore in the EnMT process (4, 7, 9). Similarly, studies in human epithelial cell EMT provided evidence that TGF-beta1 induced a marked change in epithelial cell morphology that was associated with a loss of cell-cell contacts, including decreased E-cadherin expression, inhibition of ZO-1 expression, and loss of beta-catenin association with both E-cadherin and {alpha}-catenin (98). Comparing EnMT and EMT, we must keep in mind, though, that the adherens junctions in endothelial cells are composed of VE-cadherin and ADAM 15, whereas a central component of epithelial cell-cell adherens junctions is E-cadherin, and a hallmark of EMT in development, cancer, and fibrosis is the loss of E-cadherin expression (Fig. 1) (53, 74, 81). Tian and Phillips (98) have proposed that the cellular events observed during the EMT are the result of the interaction between two different intercellular signaling pathways, one initiated by TGF-beta and the other by Wnt. Recent studies demonstrated a participation of members of the Wnt-signaling pathway (beta-catenin and TCF/Lef) in addition to TGF-beta pathways in the heart cushion development in the mouse, again suggesting an interaction between TGF-beta and Wnt pathways in the EnMT process (54) (Fig. 1).


Figure 1
View larger version (35K):
[in this window]
[in a new window]

 
Fig. 1. Schematic diagram illustrating potential mechanisms involved in endothelial-mesenchymal transition. Many initiating factors, all of which can lead to loss of cell-cell contacts, have been described. These factors are capable of activating metalloproteinase and serine protease family members and are important in loss of cell-cell contact. Following this interruption of cell-cell or cell-matrix contact, there is activation of transcription factors, which are actively involved in suppression of E-cadherins and other endothelial-specific proteins. Upregulation of a mesenchymal gene program follows. Importantly, in some situations, this process may be reversible. HGF, hepatocyte growth factor; BMP, bone morphogenetic protein; TGF, transforming growth factor; MMPs, matrix metalloproteinases.

 
In addition to TGF-beta and Wnt intercellular signaling pathways, the Notch pathway has also been proposed to be involved in EnMT. Notch signaling has been shown to operate in both vascular development and intimal lesion formation processes where EnMT is proposed to be involved (47). Studies on Notch signaling pathways in the vascular system have revealed that these pathways comprise the receptor families Notch1 and Notch4 and that Jagged1, Jagged2, and Delta4 are among their ligands (47). Of particular interest, Lindner et al. (55) demonstrated the expression of Jagged/Notch genes during the vascular response to injury and reported that the soluble Jagged1 protein modulated cell phenotype via alterations in the intercellular junctions as well as in focal adhesions. However, few studies have focused specifically on the role of the Notch signaling pathway in the EnMT process, particularly with regard to endothelial cell-cell interactions. Recent work by Noseda et al. (66, 67) suggests that expression of activated Notch1 or Notch4 in endothelial cells can cause transition to a mesenchymal phenotype. An important role for Notch-mediated EnMT during endocardial cushion formation has also been suggested (10, 99). Furthermore, Liebner et al. (54) have found that the complex Jagged/Notch promotes EnMT via transcriptional induction of Snail during heart cushion development. Snail is a DNA-binding factor that recognizes E box motifs in target promoters, including E-cadherin, and has been shown to be a critical mediator of EMT (53, 65). Other repressors of E-cadherin and important inducers of epithelial EMT are the zinc finger protein SIP1 and Twist (42, 81, 107). However, little work has been done examining specifically the role of these or analogous repressors in EnMT.

Cell adhesion, migration and EnMT. Acquisition of a migratory phenotype, preceeded by changes in cell shape and in interactions with the extracellular matrix (ECM), has been proposed as critical during the EMT process (48, 88, 97). Whether the same is true for EnMT is unclear but very likely. We will therefore briefly review some general aspects of cell adhesion, spreading, interactions with ECM, and migration as they might relate to EnMT.

It is now well established that most ECM molecules participate in the regulation of cytoskeletal organization, cell adhesion, spreading, migration, cell differentiation, growth, and apoptosis in response to various soluble factors and mechanical stimuli (42). Both in vivo and cell culture studies have suggested that these cellular events are determined through the action of tractional or tensile forces that are generated within the cell cytoskeleton and are physically resisted by ECM attachment points, focal adhesions. The balance between tensile forces and ECM resistance has been termed tensegrity, and alterations in this balance might actively contribute to control of cell shape and might be a critical determinant of cell migration (45). Focal adhesions, like adherens junctions, are thought to be important not only as structural links between the ECM and the cytoskeleton but also as sites for signal transduction through integrins present at these sites (86). Integrins, in addition to mediating cell binding to ECM components, also govern focal adhesion formation, cell spreading, migration, and differentiation (23, 96). These cellular events include the formation of ruffles, lamellipodia, filopodia, and microspikes at the leading edge of migrating cells and have been associated with activation and regulation of Rho family GTPases, including Rac and RhoA (23, 70, 72, 96).

Of particular note, a recent study in human microvascular endothelial cells provides evidence suggesting that Rac, but not Rho or Cdc42, is activated during endothelial cell adhesion to laminin-8 and that it is crucial for integrin-mediated cell spreading and migration (31). An important role for RhoA in the formation or disassembly of focal adhesions and endothelial migration during angiogenesis in vivo and in vitro has also been recently proposed (40, 49). Of further interest, recent work demonstrates that shear stress significantly enhances endothelial cell migration by modulating the tractional forces through the small GTPase pathway (100). Most recently, studies show that Rho-associated kinases have a critical role in the mesenchymal cell invasion/migration that occurs late in the EnMT process (84).

Given that changes in cell shape, interactions with the ECM, and acquisition of migratory capabilities have been proposed as critical during the EMT process, we suggest that the experimental findings reviewed above represent an important frame of reference for a better understanding of the EnMT process. Studies are necessary to gain insights into mechanisms that regulate the endothelial cell migration and transition in EnMT.

Proteases, endothelial cell migration, and EnMT. As discussed above, the balance between tensile forces generated within the cytoskeleton and the resistance to these forces offered by the ECM is a determinant not only of cell shape and growth but also of cell migration (21, 45). Cell migration is dependent on degradation of ECM (pericellular proteolysis), and cells produce proteases exhibiting different activities and substrate specificities. Most of the proteases involved in releasing cells from their localized state within the ECM belong to the metalloproteinase and serine protease families (80).

Numerous studies have suggested an important role for matrix metalloproteinases (MMPs) in morphogenesis, migration, and tissue remodeling during embryonic development and in various pathological conditions (106). However, few studies have addressed the role of MMPs in the EnMT process, and controversy exists regarding participation of MMPs in this process. For instance, MMP-2 has been proposed to play an essential role in producing epithelial-mesenchymal transformations in the avian embryo, and whereas certain studies proposed that MMP-2 participates in the loss of cell-cell contacts by removal of cadherins, other reports suggested that MMP-2 is only expressed as the cells begin to migrate and acquire mesenchymal characteristics and not specifically during the loss of cell-cell contacts (26, 32, 91). Several studies have reported that MMP-2 directly affects cell migration by degradation of specific ECM components (1, 32, 91, 92). Other studies showed the localization of MMPs at the focal adhesion sites and lamellipodia during cell detachment on the onset of migration (16) and therefore proposed the role of MMPs in EMT. These reports are certainly compatible with observations showing increased MMP expression in cells exhibiting a mesenchymal compared with epithelial phenotype and suggest the role of MMPs in the EnMT process.

One of the most studied members of the serine protease family is the urokinase type plasminogen receptor (uPAR)-urokinase type plasminogen activator (uPA) system and its inhibitor plasminogen activator inhibitor (PAI), which may convert plasminogen to plasmin. uPAR-uPA can degrade ECM components and indirectly activate latent growth factors, such as FGF and TGF-beta as well as MMPs (71, 78, 80). Apart from its proteolytic activity, the uPAR-uPA system has been suggested to be involved in cell adhesion and migration and to be expressed at cell-cell contacts, focal adhesion sites, and at the leading edges of some migrating cells (77, 102). Studies have shown the colocalization of uPAR with integrins at the lamellipodia of migrating cells, suggesting a functional cooperation between these molecules during cell migration (22, 77, 108). Of particular significance, recent studies by Czekay et al. (19) provide evidence that PAI-1 participates in the detachment of cells from ECM by inactivating integrins. Yet, few studies have directly evaluated the role of the uPAR-uPA system in EnMT. Clearly, serine proteases are critical in early vascular morphogenesis (2). In addition, urokinase activity has been reported during early stages of avian heart development, suggesting an important role for this serine protease in the onset of ventricular trabeculation and mesenchymal cell migration during endocardial cushion tissue development (59). Cell culture studies provide evidence for an important role for uPA in the transition of endocardial cells into cardiac mesenchymal cells in a process that does not involve plasminogen conversion (33). Increased uPAR-uPA expression has been described at focal adhesion sites on migrating endothelial cells in response to mechanical wounding in vitro (75). In this regard, increased expression of uPAR-uPA has been detected by Arciniegas et al. (5) in the intimal thickening of the chick embryonic aortic wall where EnMT was suggested to play a role as well as in neointima of human atherosclerotic arteries (94).

Another important serine protease is thrombin, which, in addition to playing an essential role in hemostasis and thrombosis, is also involved in tissue repair and remodeling, angiogenesis, embryonic development, progression of atherosclerosis and restenosis, and tumor invasion and metastasis (34, 58, 60, 61, 73). Among other functions, thrombin signaling regulates cell shape, migration, and differentiation, and promotes MMP activation (25, 61). Thrombin signaling appears to be mediated, at least in part, by specific thrombin receptors, particularly the protease-activated receptor-1 (PAR-1) (18, 110). With regard to potential participation of thrombin and PAR-1 in the EnMT process, a recent study demonstrated the presence of PAR-1 in cultured endothelial cells that are detaching and migrating from the monolayer, as well as in some newly appearing mesenchymal cells expressing {alpha}-SM actin (3). Moreover, addition of thrombin to growth-arrested embryonic endothelial cell cultures stimulated cell migration. This study also suggested that both thrombin and PAR-1 are involved in the remodeling of the embryonic aortic wall and in the development of intimal thickening. In human arteries, PAR-1 expression has been reported in early atherosclerotic neointimal lesions but not in the media. This expression was correlated with the presence of mesenchymal-like cells of unknown origin in the intima (64). Studies using tumor cells have provided evidence that PAR-1, in cooperation with integrins, promotes tumor cell migration and invasion through focal adhesion formation and cytoskeletal reorganization (28, 110).

Of further interest, thrombin-PAR-1, like uPAR-uPA, has been suggested to induce release of certain growth factors (61), which constitute important upstream regulators of signal transduction pathways involved in both EMT and EnMT (7, 13, 21, 38, 44, 5355, 79, 98, 111). However, the mechanisms controlling the production of these factors are not yet completely understood. Hemodynamic forces, such as shear stress, tensile stress, and internal tension of the cytoskeleton, can modulate the expression of some serine proteases and MMPs (50) and induce local production and activation of growth factors, including FGF, PDGF, VEGF, and TGF-beta-superfamily members (89). In addition, hemodynamic forces can modulate endothelial cell morphology and cell migration, supposedly by activation of Rho-GTPase family members (21, 89, 100). Thus one can speculate that hemodynamic alterations may be one important upstream regulator of the EnMT process. Additional work is required for a better understanding of contribution of mechanical forces to EnMT and of the specific roles that MMPs and serine proteases play in this process.

Reversibility of EMT and EnMT. During embryogenesis, a process that is essentially the reverse of EMT, termed MET, occurs during organ morphogeneis (20, 38, 68, 69, 74). Control or upregulation of cadherin expression through developmental and spatially regulated expression of molecules such as BMP-7 and HGF appear critical for this process (68, 69). These observations suggested that the EMT process in mature organs may be reversible. Indeed, exciting new studies in the kidney suggest that a regenerative program can be initiated in the injured kidney that bears resemblance to renal development (53, 68, 69). It has been demonstrated that remission, as well as substantial regression, can be achieved by exogenous recombinant human BMP-7 (rhBMP-7) in the fibrotic kidney (68, 69, 111). rhBMP-7 reverses EMT, inhibits the release of proinflammatory/fibrogenic cytokines from tubular epithelial cells, and prevents apoptosis to repair and restore normal renal architecture. rhBMP-7 binds to Alk3 and Alk6, which function via phosphorylation of Smad 1, 5, and 8 to increase in E-cadherin expression, counteracting the TGF-beta-induced Alk5- and Smad 2- and Smad 3-mediated decrease in E-cadherin expression. Thus it seems strategies aimed at reversing EMT may have a significant, positive effect on fibrotic organ injuries.

Less is known regarding the reversibility of EnMT. One study, in which EnMT was shown to be induced by withdrawal of FGF, showed that restoration of the endothelial phenotype could be restored by restoring FGF to the cells. More studies are obviously necessary to determine the reversibility of the EnMT process in vitro and in vivo.

Conclusions. The intent of this review was to present the current state of knowledge regarding the factors and mechanisms operating during the EnMT process, which occurs not only during embryonic development but also in the pathogenesis of various vascular diseases. We intended to reveal the complexity of the EnMT process, which seems to progress through a series of important steps (Fig. 1). Unfortunately, these have generally been analyzed separately and in different cell systems by different investigators. Additional studies are required for a better understanding of the molecular mechanisms of EnMT regulation operating in vivo and in vitro to control the maintenance of intercellular junctions and cell-cell and cell-matrix interactions. Proteome and genome level studies of the upstream regulators that participate in the control of transcription factors that repress VE-cadherin expression and thus initiate the EnMT are needed. Information is needed regarding the factors that regulate serine protease and MMP expression in endothelial cells, which ultimately affect the balance between the synthesis and degradation of ECM components and thus regulate cell migration and cell phenotype. Targeted pharmacological inhibition of serine-proteases and MMPs or knockdown with antisense or small interfering RNA technologies may provide a cornerstone for these investigations. Phospho-activated NF-{kappa}B is essential for EMT and tumor metastasis (43) and has been implicated in the progression of atherosclerosis and cancer, diseases in which EnMT may have pathological relevance. Therefore, studies targeting NF-{kappa}B may provide critical mechanistic insights into the EnMT process. Reporter-gene transgenic mice engineered to carry endothelium-specific reporters (such as flk-1+/lacZ, tie-2/lacZ, and vWF/lacZ) provide a useful system for exploring EnMT. Conditional endothelial cell-specific transgenic knockout and/or knockin models for EnMT regulatory genes, such as beta-catenin, may also provide fundamental insights. Finally, additional studies will be required to determine whether EnMT is a reversible process as has been proposed during EMT in tumorigenesis, embryogenesis, and fibrosis, and if so, whether treatments directed toward this process have significant effects on vascular disease (79).


    GRANTS
 TOP
 ABSTRACT
 GRANTS
 REFERENCES
 
This work was supported by National Heart, Lung, and Blood Institute Grants HL-57144-09 and HL-14985-33 (K. R. Stenmark), K08-HL-070940 (I. S. Douglas), FONACIT Grant S1-2000000038 (E. Arciniegas), and American Heart Association Grant 0550056Z (M. G. Frid).


    FOOTNOTES
 

Address for reprint requests and other correspondence: K. R. Stenmark, Univ. of Colorado at Denver and Health Sciences Center, 4200 E. 9th Ave., Campus Box B131, Denver, CO 80262 (e-mail: kurt.stenmark{at}uchsc.edu)


    REFERENCES
 TOP
 ABSTRACT
 GRANTS
 REFERENCES
 

  1. Aimes RT, Quigley JP. Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem 270: 5872–5876, 1995.[Abstract/Free Full Text]
  2. Aimes RT, Zijlstra A, Hooper JD, Ogbourne SM, Sit ML, Fuchs S, Gotley DC, Quigley JP, Antalis TM. Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis. Thromb Haemost 89: 561–572, 2003.[ISI][Medline]
  3. Archiniegas E, Neves CY, Candelle D, Cardier JE. Thrombin and its protease-activated receptor-1 (PAR1) participate in the endothelial-mesenchymal transdifferentiation process. DNA Cell Biol 23: 815–825, 2004.[ISI][Medline]
  4. Arciniegas E, Neves CY, Carrillo LM, Zambrano EA, Ramirez R. Endothelial-mesenchymal transition occurs during embryonic pulmonary artery development. Endothelium 12: 193–200, 2005.[CrossRef][ISI][Medline]
  5. Arciniegas E, Neves YC, Carrillo LM. Potential role for insulin-like growth factor II and vitronectin in the endothelial-mesenchymal transition process. Differentiation 74: 277–292, 2006.[CrossRef][ISI][Medline]
  6. Arciniegas E, Parada D, Graterol A. Mechanically altered embryonic chicken endothelial cells change their phenotype to an epithelioid phenotype. Anat Rec A Discov Mol Cell Evol Biol 270: 67–81, 2003.[Medline]
  7. Arciniegas E, Ponce L, Hartt Y, Graterol A, Carlini RG. Intimal thickening involves transdifferentiation of embryonic endothelial cells. Anat Rec 258: 47–57, 2000.[CrossRef][Medline]
  8. Arciniegas E, Servin M, Arguello C, Mota M. Development of the aorta in the chick embryo: structural and ultrastructural study. Atherosclerosis 76: 219–235, 1989.[CrossRef][ISI][Medline]
  9. Arciniegas E, Sutton AB, Allen TD, Schor AM. Transforming growth factor beta 1 promotes the differentiation of endothelial cells into smooth muscle-like cells in vitro. J Cell Sci 103: 521–529, 1992.[Abstract]
  10. Armstrong EJ, Bischoff J. Heart valve development: endothelial cell signaling and differentiation. Circ Res 95: 459–470, 2004.[Abstract/Free Full Text]
  11. Beranek JT. Vascular endothelium-derived cells containing smooth muscle actin are present in restenosis. Lab Invest 72: 771, 1995.[ISI][Medline]
  12. Beranek JT, Cavarocchi NC. Undifferentiated vascular endothelial cells in coronary allograft atherosclerosis. Int J Cardiol 28: 127–128, 1990.[CrossRef][ISI][Medline]
  13. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL, Moses HL. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 12: 27–36, 2001.[Abstract/Free Full Text]
  14. Blanco D, Vicent S, Elizegi E, Pino I, Fraga MF, Esteller M, Saffiotti U, Lecanda F, Montuenga LM. Altered expression of adhesion molecules and epithelial-mesenchymal transition in silica-induced rat lung carcinogenesis. Lab Invest 84: 999–1012, 2004.[CrossRef][ISI][Medline]
  15. Boyer AS, Ayerinskas II, Vincent EB, McKinney LA, Weeks DL, Runyan RB. TGFbeta2 and TGFbeta3 have separate and sequential activities during epithelial-mesenchymal cell transformation in the embryonic heart. Dev Biol 208: 530–545, 1999.[CrossRef][ISI][Medline]
  16. Brown PD, Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol 6: 967–974, 1995.[Abstract/Free Full Text]
  17. Chilosi M, Poletti V, Zamo A, Lestani M, Montagna L, Piccoli P, Pedron S, Bertaso M, Scarpa A, Murer B, Cancellieri A, Maestro R, Semenzato G, Doglioni C. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 162: 1495–1502, 2003.[Abstract/Free Full Text]
  18. Coughlin SR. How the protease thrombin talks to cells. Proc Natl Acad Sci USA 96: 11023–11027, 1999.[Abstract/Free Full Text]
  19. Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 160: 781–791, 2003.[Abstract/Free Full Text]
  20. Dahl U, Sjodin A, Larue L, Radice GL, Cajander S, Takeichi M, Kemler R, Semb H. Genetic dissection of cadherin function during nephrogenesis. Mol Cell Biol 22: 1474–1487, 2002.[Abstract/Free Full Text]
  21. DeClerck YA, Mercurio AM, Stack MS, Chapman HA, Zutter MM, Muschel RJ, Raz A, Matrisian LM, Sloane BF, Noel A, Hendrix MJ, Coussens L, Padarathsingh M. Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am J Pathol 164: 1131–1139, 2004.[Abstract/Free Full Text]
  22. Degryse B, Orlando S, Resnati M, Rabbani SA, Blasi F. Urokinase/urokinase receptor and vitronectin/alpha(v)beta(3) integrin induce chemotaxis and cytoskeleton reorganization through different signaling pathways. Oncogene 20: 2032–2043, 2001.[CrossRef][ISI][Medline]
  23. DeMali KA, Wennerberg K, Burridge K. Integrin signaling to the actin cytoskeleton. Curr Opin Cell Biol 15: 572–582, 2003.[CrossRef][ISI][Medline]
  24. DeRuiter MC, Poelmann RE, VanMunsteren JC, Mironov V, Markwald RR, Gittenberger-de Groot AC. Embryonic endothelial cells transdifferentiate into mesenchymal cells expressing smooth muscle actins in vivo and in vitro. Circ Res 80: 444–451, 1997.[Abstract/Free Full Text]
  25. Duhamel-Clerin E, Orvain C, Lanza F, Cazenave JP, Klein-Soyer C. Thrombin receptor-mediated increase of two matrix metalloproteinases, MMP-1 and MMP-3, in human endothelial cells. Arterioscler Thromb Vasc Biol 17: 1931–1938, 1997.[Abstract/Free Full Text]
  26. Duong TD, Erickson CA. MMP-2 plays an essential role in producing epithelial-mesenchymal transformations in the avian embryo. Dev Dyn 229: 42–53, 2004.[CrossRef][ISI][Medline]
  27. Eisenberg LM, Markwald RR. Molecular regulation of atrioventricular valvuloseptal morphogenesis. Circ Res 77: 1–6, 1995.[Free Full Text]
  28. Even-Ram SC, Maoz M, Pokroy E, Reich R, Katz BZ, Gutwein P, Altevogt P, Bar-Shavit R. Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha vbeta 5 integrin. J Biol Chem 276: 10952–10962, 2001.[Abstract/Free Full Text]
  29. Frid MG, Brunetti JA, Burke DL, Carpenter TC, Davie NJ, Reeves JT, Roedersheimer MT, van Rooijen N, Stenmark KR. Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am J Pathol 168: 659–669, 2006.[Abstract/Free Full Text]
  30. Frid MG, Kale VA, Stenmark KR. Mature vascular endothelium can give rise to smooth muscle cells via endothelial-mesenchymal transdifferentiation: in vitro analysis. Circ Res 90: 1189–1196, 2002.[Abstract/Free Full Text]
  31. Fujiwara H, Gu J, Sekiguchi K. Rac regulates integrin-mediated endothelial cell adhesion and migration on laminin-8. Exp Cell Res 292: 67–77, 2004.[CrossRef][ISI][Medline]
  32. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 277: 225–228, 1997.[Abstract/Free Full Text]
  33. Gorny KN, Brauer PR. Urokinase regulates embryonic cardiac cushion cell migration without converting plasminogen. Anat Rec 256: 269–278, 1999.[CrossRef][Medline]
  34. Griffin CT, Srinivasan Y, Zheng YW, Huang W, Coughlin SR. A role for thrombin receptor signaling in endothelial cells during embryonic development. Science 293: 1666–1670, 2001.[Abstract/Free Full Text]
  35. Hall SM, Hislop AA, Haworth SG. Origin, differentiation, and maturation of human pulmonary veins. Am J Respir Cell Mol Biol 26: 333–340, 2002.[Abstract/Free Full Text]
  36. Hall SM, Hislop AA, Pierce CM, Haworth SG. Prenatal origins of human intrapulmonary arteries: formation and smooth muscle maturation. Am J Respir Cell Mol Biol 23: 194–203, 2000.[Abstract/Free Full Text]
  37. Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel) 154: 8–20, 1995.[ISI][Medline]
  38. Hay ED. The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev Dyn 233: 706–720, 2005.[CrossRef][ISI][Medline]
  39. Hewett PW, Murray JC. Immunomagnetic purification of human microvessel endothelial cells using Dynabeads coated with monoclonal antibodies to PECAM-1. Eur J Cell Biol 62: 451–454, 1993.[ISI][Medline]
  40. Hoang MV, Whelan MC, Senger DR. Rho activity critically and selectively regulates endothelial cell organization during angiogenesis. Proc Natl Acad Sci USA 101: 1874–1879, 2004.[Abstract/Free Full Text]
  41. Hu Y, Zhang Z, Torsney E, Afzal AR, Davison F, Metzler B, Xu Q. Abundant progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoE-deficient mice. J Clin Invest 113: 1258–1265, 2004.[CrossRef][ISI][Medline]
  42. Huang S, Ingber DE. Shape-dependent control of cell growth, differentiation, and apoptosis: switching between attractors in cell regulatory networks. Exp Cell Res 261: 91–103, 2000.[CrossRef][ISI][Medline]
  43. Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A, Pehamberger H, Kraut N, Beug H, Wirth T. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 114: 569–581, 2004.[CrossRef][ISI][Medline]
  44. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43: 13S–24S, 2004.[Abstract/Free Full Text]
  45. Ingber DE. Cellular tensegrity: defining new rules of biological design that govern the cytoskeleton. J Cell Sci 104: 613–627, 1993.[ISI][Medline]
  46. Ishisaki A, Hayashi H, Li AJ, Imamura T. Human umbilical vein endothelium-derived cells retain potential to differentiate into smooth muscle-like cells. J Biol Chem 278: 1303–1309, 2003.[Abstract/Free Full Text]
  47. Iso T, Hamamori Y, Kedes L. Notch signaling in vascular development. Arterioscler Thromb Vasc Biol 23: 543–553, 2003.[Abstract/Free Full Text]
  48. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112: 1776–1784, 2003.[CrossRef][ISI][Medline]
  49. Kanda S, Miyata Y, Kanetake H. Role of focal adhesion formation in migration and morphogenesis of endothelial cells. Cell Signal 16: 1273–1281, 2004.[CrossRef][ISI][Medline]
  50. Kenagy RD, Fischer JW, Davies MG, Berceli SA, Hawkins SM, Wight TN, Clowes AW. Increased plasmin and serine proteinase activity during flow-induced intimal atrophy in baboon PTFE grafts. Arterioscler Thromb Vasc Biol 22: 400–404, 2002.[Abstract/Free Full Text]
  51. Kohler A, Jostarndt-Fogen K, Rottner K, Alliegro MC, Draeger A. Intima-like smooth muscle cells: developmental link between endothelium and media? Anat Embryol (Berl) 200: 313–323, 1999.[CrossRef][Medline]
  52. Lampugnani MG, Dejana E. Interendothelial junctions: structure, signalling and functional roles. Curr Opin Cell Biol 9: 674–682, 1997.[CrossRef][ISI][Medline]
  53. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172: 973–981, 2006.[Abstract/Free Full Text]
  54. Liebner S, Cattelino A, Gallini R, Rudini N, Iurlaro M, Piccolo S, Dejana E. Beta-catenin is required for endothelial-mesenchymal transformation during heart cushion development in the mouse. J Cell Biol 166: 359–367, 2004.[Abstract/Free Full Text]
  55. Lindner V, Booth C, Prudovsky I, Small D, Maciag T, Liaw L. Members of the Jagged/Notch gene families are expressed in injured arteries and regulate cell phenotype via alterations in cell matrix and cell-cell interaction. Am J Pathol 159: 875–883, 2001.[Abstract/Free Full Text]
  56. Lipton BH, Bensch KG, Karasek MA. Histamine-modulated transdifferentiation of dermal microvascular endothelial cells. Exp Cell Res 199: 279–291, 1992.[CrossRef][ISI][Medline]
  57. Liu C, Nath KA, Katusic ZS, Caplice NM. Smooth muscle progenitor cells in vascular disease. Trends Cardiovasc Med 14: 288–293, 2004.[CrossRef][ISI][Medline]
  58. Maragoudakis ME, Tsopanoglou NE, Andriopoulou P. Mechanism of thrombin-induced angiogenesis. Biochem Soc Trans 30: 173–177, 2002.[CrossRef][ISI][Medline]
  59. McGuire PG, Orkin RW. Urokinase activity in the developing avian heart: a spatial and temporal analysis. Dev Dyn 193: 24–33, 1992.[ISI][Medline]
  60. McNamara CA, Sarembock IJ, Bachhuber BG, Stouffer GA, Ragosta M, Barry W, Gimple LW, Powers ER, Owens GK. Thrombin and vascular smooth muscle cell proliferation: implications for atherosclerosis and restenosis. Semin Thromb Hemost 22: 139–144, 1996.[ISI][Medline]
  61. Minami T, Sugiyama A, Wu SQ, Abid R, Kodama T, Aird WC. Thrombin and phenotypic modulation of the endothelium. Arterioscler Thromb Vasc Biol 24: 41–53, 2004.[Abstract/Free Full Text]
  62. Mironov Y, Hill C, Starcher B, Shin J, Hoffman S, Markwald R. Endothelial-mesenchymal transformation in atherogenesis: a recapitulation of embryonic heart cushion tissue morphogenesis. Ann Biomed Eng 23: S29A, 1995.
  63. Nakajima Y, Yamagishi T, Hokari S, Nakamura H. Mechanisms involved in valvuloseptal endocardial cushion formation in early cardiogenesis: roles of transforming growth factor (TGF)-beta and bone morphogenetic protein (BMP). Anat Rec 258: 119–127, 2000.[CrossRef][Medline]
  64. Nelken NA, Soifer SJ, O'Keefe J, Vu TK, Charo IF, Coughlin SR. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 90: 1614–1621, 1992.[ISI][Medline]
  65. Nieto MA. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol 3: 155–166, 2002.[CrossRef][ISI][Medline]
  66. Noseda M, Fu Y, Niessen K, Wong F, Chang L, McLean G, Karsan A. Smooth muscle alpha-actin is a direct target of Notch/CSL. Circ Res 98: 1468–1470, 2006.[Abstract/Free Full Text]
  67. Noseda M, McLean G, Niessen K, Chang L, Pollet I, Montpetit R, Shahidi R, Dorovini-Zis K, Li L, Beckstead B, Durand RE, Hoodless PA, Karsan A. Notch activation results in phenotypic and functional changes consistent with endothelial-to-mesenchymal transformation. Circ Res 94: 910–917, 2004.[Abstract/Free Full Text]
  68. Okada H, Kalluri R. Cellular and molecular pathways that lead to progression and regression of renal fibrogenesis. Curr Mol Med 5: 467–474, 2005.[CrossRef][ISI][Medline]
  69. Okada H, Kalluri R. Recapitulation of kidney development paradigms by BMP-7 reverses chronic renal injury. Clin Exp Nephrol 9: 100–101, 2005.[CrossRef][Medline]
  70. Oloumi A, McPhee T, Dedhar S. Regulation of E-cadherin expression and beta-catenin/Tcf transcriptional activity by the integrin-linked kinase. Biochim Biophys Acta 1691: 1–15, 2004.[Medline]
  71. Ossowski L, Aguirre-Ghiso JA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 12: 613–620, 2000.[CrossRef][ISI][Medline]
  72. Parker KK, Brock AL, Brangwynne C, Mannix RJ, Wang N, Ostuni E, Geisse NA, Adams JC, Whitesides GM, Ingber DE. Directional control of lamellipodia extension by constraining cell shape and orienting cell tractional forces. FASEB J 16: 1195–1204, 2002.[Abstract/Free Full Text]
  73. Patterson C, Stouffer GA, Madamanchi N, Runge MS. New tricks for old dogs: nonthrombotic effects of thrombin in vessel wall biology. Circ Res 88: 987–997, 2001.[Abstract/Free Full Text]
  74. Peinado H, Portillo F, Cano A. Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol 48: 365–375, 2004.[CrossRef][ISI][Medline]
  75. Pepper MS, Sappino AP, Stocklin R, Montesano R, Orci L, Vassalli JD. Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol 122: 673–684, 1993.[Abstract/Free Full Text]
  76. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, Reid LM, Tuder RM. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 43: 25S–32S, 2004.[Abstract/Free Full Text]
  77. Planus E, Barlovatz-Meimon G, Rogers RA, Bonavaud S, Ingber DE, Wang N. Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading. J Cell Sci 110: 1091–1098, 1997.[Abstract]
  78. Preissner KT, Kanse SM, May AE. Urokinase receptor: a molecular organizer in cellular communication. Curr Opin Cell Biol 12: 621–628, 2000.[CrossRef][ISI][Medline]
  79. Prindull G, Zipori D. Environmental guidance of normal and tumor cell plasticity: epithelial mesenchymal transitions as a paradigm. Blood 103: 2892–2899, 2004.[Abstract/Free Full Text]
  80. Quigley JP, Berkenpas MB, Aimes RT, Chen JM. Serine protease and metalloprotease cascade systems involved in pericellular proteolysis. Cell Differ Dev 32: 263–275, 1990.[CrossRef][ISI][Medline]
  81. Radisky DC. Epithelial-mesenchymal transition. J Cell Sci 118: 4325–4326, 2005.[Free Full Text]
  82. Robson EJ, Khaled WT, Abell K, Watson CJ. Epithelial-to-mesenchymal transition confers resistance to apoptosis in three murine mammary epithelial cell lines. Differentiation 74: 254–264, 2006.[CrossRef][ISI][Medline]
  83. Romero LI, Zhang DN, Herron GS, Karasek MA. Interleukin-1 induces major phenotypic changes in human skin microvascular endothelial cells. J Cell Physiol 173: 84–92, 1997.[CrossRef][ISI][Medline]
  84. Sakabe M, Ikeda K, Nakatani K, Kawada N, Imanaka-Yoshida K, Yoshida T, Yamagishi T, Nakajima Y. Rho kinases regulate endothelial invasion and migration during valvuloseptal endocardial cushion tissue formation. Dev Dyn 235: 94–104, 2006.[CrossRef][ISI][Medline]
  85. Sarkisov DS, Kolokol'chikova EG, Kaem RI, Pal'tsyn AA. [Vascular changes in maturing granulation tissue]. Biull Eksp Biol Med 105: 501–503, 1988.[CrossRef][Medline]
  86. Sastry SK, Burridge K. Focal adhesions: a nexus for intracellular signaling and cytoskeletal dynamics. Exp Cell Res 261: 25–36, 2000.[CrossRef][ISI][Medline]
  87. Sata M. Role of circulating vascular progenitors in angiogenesis, vascular healing, and pulmonary hypertension: lessons from animal models. Arterioscler Thromb Vasc Biol 26: 1008–1014, 2006.[Abstract/Free Full Text]
  88. Savagner P. Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 23: 912–923, 2001.[CrossRef][ISI][Medline]
  89. Shyy JY, Chien S. Role of integrins in cellular responses to mechanical stress and adhesion. Curr Opin Cell Biol 9: 707–713, 1997.[CrossRef][ISI][Medline]
  90. Slattery C, McMorrow T, Ryan MP. Overexpression of E2A proteins induces epithelial-mesenchymal transition in human renal proximal tubular epithelial cells suggesting a potential role in renal fibrosis. FEBS Lett 580: 4021–4030, 2006.[CrossRef][ISI][Medline]
  91. Song W, Jackson K, McGuire PG. Degradation of type IV collagen by matrix metalloproteinases is an important step in the epithelial-mesenchymal transformation of the endocardial cushions. Dev Biol 227: 606–617, 2000.[CrossRef][ISI][Medline]
  92. Song W, Majka SM, McGuire PG. Hepatocyte growth factor expression in the developing myocardium: evidence for a role in the regulation of the mesenchymal cell phenotype and urokinase expression. Dev Dyn 214: 92–100, 1999.[CrossRef][ISI][Medline]
  93. Springhorn JP, Madri JA, Squinto SP. Human capillary endothelial cells from abdominal wall adipose tissue: isolation using an anti-pecam antibody. In Vitro Cell Dev Biol Anim 31: 473–481, 1995.[CrossRef]
  94. Steins MB, Padro T, Schwaenen C, Ruiz S, Mesters RM, Berdel WE, Kienast J. Overexpression of urokinase receptor and cell surface urokinase-type plasminogen activator in the human vessel wall with different types of atherosclerotic lesions. Blood Coagul Fibrinolysis 15: 383–391, 2004.[CrossRef][ISI][Medline]
  95. Stenmark K, Davie N, Frid M, Gerasimovskaya E, Das M. Role of the adventitia in pulmonary vascular remodeling. Physiology 21: 134–145, 2006.[Abstract/Free Full Text]
  96. Stupack DG, Cheresh DA. Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci 115: 3729–3738, 2002.[Abstract/Free Full Text]
  97. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442–454, 2002.[CrossRef][ISI][Medline]
  98. Tian YC, Phillips AO. Interaction between the transforming growth factor-beta type II receptor/Smad pathway and beta-catenin during transforming growth factor-beta1-mediated adherens junction disassembly. Am J Pathol 160: 1619–1628, 2002.[Abstract/Free Full Text]
  99. Timmerman LA, Grego-Bessa J, Raya A, Bertran E, Perez-Pomares JM, Diez J, Aranda S, Palomo S, McCormick F, Izpisua-Belmonte JC, de la Pompa JL. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev 18: 99–115, 2004.[Abstract/Free Full Text]
  100. Tzima E. Role of small GTPases in endothelial cytoskeletal dynamics and the shear stress response. Circ Res 98: 176–185, 2006.[Abstract/Free Full Text]
  101. Voyta JC, Via DP, Butterfield CE, Zetter BR. Identification and isolation of endothelial cells based on their increased uptake of acetylated-low density lipoprotein. J Cell Biol 99: 2034–2040, 1984.[Abstract/Free Full Text]
  102. Wang N, Planus E, Pouchelet M, Fredberg JJ, Barlovatz-Meimon G. Urokinase receptor mediates mechanical force transfer across the cell surface. Am J Physiol Cell Physiol 268: C1062–C1066, 1995.[Abstract/Free Full Text]
  103. Ward C, Robertson H, Forrest IA, Lordan J, Murphy D, Dark JH, Corris PA, Jones DE, Kirby JA. Hypothesis: epithelial-to-mesenchymal transition is a common cause of chronic allograft failure. Transplant Proc 37: 977–980, 2005.[CrossRef][ISI][Medline]
  104. Willis BC, duBois RM, Borok Z. Epithelial origin of myofibroblasts during fibrosis in the lung. Proc Am Thorac Soc 3: 377–382, 2006.[Abstract/Free Full Text]
  105. Willis BC, Liebler JM, Luby-Phelps K, Nicholson AG, Crandall ED, du Bois RM, Borok Z. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 166: 1321–1332, 2005.[Abstract/Free Full Text]
  106. Woessner J. The matrix metalloproteinase family. San Diego: Academic, 1998.
  107. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117: 927–939, 2004.[CrossRef][ISI][Medline]
  108. Yebra M, Parry GC, Stromblad S, Mackman N, Rosenberg S, Mueller BM, Cheresh DA. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. J Biol Chem 271: 29393–29399, 1996.[Abstract/Free Full Text]
  109. Yi ES, Kim H, Ahn H, Strother J, Morris T, Masliah E, Hansen LA, Park K, Friedman PJ. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am J Respir Crit Care Med 162: 1577–1586, 2000.[Abstract/Free Full Text]
  110. Yin YJ, Salah Z, Grisaru-Granovsky S, Cohen I, Even-Ram SC, Maoz M, Uziely B, Peretz T, Bar-Shavit R. Human protease-activated receptor 1 expression in malignant epithelia: a role in invasiveness. Arterioscler Thromb Vasc Biol 23: 940–944, 2003.[Abstract/Free Full Text]
  111. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9: 964–968, 2003.[CrossRef][ISI][Medline]
  112. Zeisberg M, Kalluri R. The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med 82: 175–181, 2004.[CrossRef][ISI][Medline]
  113. Zhu P, Huang L, Ge X, Yan F, Wu R, Ao Q. Transdifferentiation of pulmonary arteriolar endothelial cells into smooth muscle-like cells regulated by myocardin involved in hypoxia-induced pulmonary vascular remodelling. Int J Exp Pathol 87: 463–474, 2006.[CrossRef][ISI][Medline]



This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
N. W. Clavin, T. Avraham, J. Fernandez, S. V. Daluvoy, M. A. Soares, A. Chaudhry, and B. J. Mehrara
TGF-{beta}1 is a negative regulator of lymphatic regeneration during wound repair
Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H2113 - H2127.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. D. Nandedkar, T. R. Feroah, W. Hutchins, D. Weihrauch, K. S. Konduri, J. Wang, R. C. Strunk, M. R. DeBaun, C. A. Hillery, and K. A. Pritchard
Histopathology of experimentally induced asthma in a murine model of sickle cell disease
Blood, September 15, 2008; 112(6): 2529 - 2538.
[Abstract] [Full Text] [PDF]